~62% · $380K/day
Will the FDA approve a new GLP-1 obesity drug (beyond Ozempic/Wegovy) in 2026?
Eli Lilly, Pfizer pipeline — high-volume FDA market
Healthcare Prediction Markets
New GLP-1 drug approval at 62%, mRNA cancer vaccine breakthrough at 38%, RFK Jr. FDA process change at 42%. Healthcare prediction markets on Polymarket and Kalshi price every major FDA and policy milestone — compare cross-venue healthcare odds in one search.
~62% · $380K/day
Eli Lilly, Pfizer pipeline — high-volume FDA market
~55% · $220K/day
Long-running disease modification market
~38% · $290K/day
Moderna/Merck mRNA cancer vaccine pipeline
~42% · $340K/day
Policy change market — HHS leadership
~48% · $160K/day
Public health recovery market
Macro
Healthcare costs affect consumer spending — recession macro connection
AI
AI drug discovery markets — AI-accelerated FDA pipeline
Macro
Full macro prediction market index
Yes. Polymarket and Kalshi both carry active FDA approval markets — GLP-1 drugs (obesity treatment pipeline), Alzheimer's disease-modifying therapies, mRNA cancer vaccines, and specific PDUFA date outcomes. The GLP-1 market is the highest-volume FDA prediction market with $380K in daily trading, reflecting the massive commercial stakes around Eli Lilly and Pfizer's pipeline.
Polymarket has active markets for: FDA approval of Eli Lilly's orforglipron (oral GLP-1), FDA approval of Pfizer's danuglipron, and broader questions about new GLP-1 class approvals. With Ozempic/Wegovy already generating $15B+/year, the pipeline market is highly watched. Prediction markets price a new FDA-approved GLP-1 entrant at ~62% in 2026.
FDA approval prediction markets function like binary event bets — they resolve YES/NO based on official FDA announcements. These markets often trade well before PDUFA (target action) dates and can price in insider-knowledge-level probability faster than sell-side analyst reports. Kalshi is particularly active for pharmaceutical regulatory milestones because of its regulatory compliance framework.
Robert F. Kennedy Jr. as HHS Secretary has created an active prediction market category: FDA process change markets. Prediction markets price major FDA approval process changes at ~42%, reflecting uncertainty about the scope of his influence on established agency procedures. These markets move with RFK Jr.'s public statements and any formal FDA rule proposals.